The global market for arthropod-borne viral infections testing is projected to witness significant growth, reaching a valuation of US$ 1.9 billion by 2029. This growth, representing a Compound Annual Growth Rate (CAGR) of 5.6% from 2022, highlights the increasing demand for advanced diagnostic solutions in combating arboviral diseases worldwide.
Arboviral diseases, caused by viruses transmitted to humans through the bites of arthropods such as mosquitoes and ticks, continue to pose a significant public health challenge globally. According to recent market analysis, the arthropod-borne viral infections testing market was valued at US$ 1.3 billion in 2022, comprising 4.4% of the global infectious disease diagnostics market, which reached US$ 28 billion in 2021.
Request A Sample Research Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-11572
Despite the market’s potential for growth, challenges persist, particularly in low-income economies where accessibility to detection methods remains limited. Factors such as high healthcare costs and insufficient awareness about infectious diseases contribute to these challenges, impacting the market’s expansion.
Furthermore, the market is influenced by various macroeconomic and industry factors, including disease epidemiology, biologics licensing, and product patenting. Climate change, urbanization, and global trade also play pivotal roles in expanding the geographic distribution of disease vectors and associated arboviruses, potentially increasing the disease burden in susceptible hosts.
“While challenges persist, the evolving landscape presents opportunities for positive growth outlook,” stated FMI. “As we continue to navigate through dynamic industry variables, advancements in diagnostic technologies and increased awareness about arboviral diseases are crucial in addressing this global health concern.”
With a commitment to innovation and collaboration, stakeholders within the arthropod-borne viral infections testing market are poised to drive advancements in diagnostic solutions, ultimately contributing to improved disease management and public health outcomes worldwide.
The factors you’ve mentioned definitely favor the market potential for arthropod-borne viral infections testing:
Resurgence of Threats:
- Past Epidemics: Dengue and Zika virus outbreaks highlight the devastating impact of these infections.
- Unpredictable Nature: The re-emergence of these diseases underlines the need for constant vigilance and improved diagnostic tools.
Growing Government Focus:
- Public Health Initiatives: Increased government efforts to combat arboviral infections create a demand for better testing solutions.
- Global Collaboration: Programs like GEIS showcase a commitment to international cooperation in disease surveillance and mitigation.
These points demonstrate a strong need for accurate and efficient testing methods to identify and control arthropod-borne viral infections. This translates to a significant market opportunity for companies developing and providing such tests.
Request Customization of Report: https://www.futuremarketinsights.com/customization-available/rep-gb-11572
Competitive Landscape:
Providers of testing for arthropod-borne viral infections are channeling investments into advancing the research and development of rapid test kits, aiming for swift and accurate diagnosis with minimal margin of error.
- In November 2021, Achico, a healthcare technology firm based in Switzerland, unveiled its breakthrough in the development of diagnostic kits for dengue fever. These innovative kits rely on Achico’s DNA aptamer technology platform, which has already demonstrated its effectiveness in diagnosing COVID-19.
Key Companies Profiled:
- Thermo Fisher Scientific Inc.
- Roche Molecular Systems Inc.
- bioMérieux SA
- InBios International Inc.
- NovaTec Immundiagnostica GmbH
- Euroimmun AG (Sub. PerkinElmer)
- Quest Diagnostics
- Certest Biotec S.L.
- Response Biomedical Corp.
- Chembio Diagnostic Systems Inc.
- Abbott Laboratories
Key Segments of Arthropod-borne Viral Infections Testing Industry Survey:
Arthropod-borne Viral Infections Testing Market by Test Type:
- ELISA-based Tests for Arthropod-borne Viral Infections Testing
- RT-PCR-based Tests for Arthropod-borne Viral Infections Testing
- Immunochromatography Rapid Diagnosis for Arthropod-borne Viral Infections Testing
Arthropod-borne Viral Infections Testing Market by End User:
- Arthropod-borne Viral Infections in Testing Hospitals
- Arthropod-borne Viral Infections in Public Health Laboratories
- Arthropod-borne Viral Infections in Diagnostic Centres
- Others
Arthropod-borne Viral Infections Testing Market by Region:
- North America Arthropod-borne Viral Infections Testing Market
- Latin America Arthropod-borne Viral Infections Testing Market
- Europe Arthropod-borne Viral Infections Testing Market
- East Asia Arthropod-borne Viral Infections Testing Market
- South Asia & Pacific Arthropod-borne Viral Infections Testing Market
- Middle East & Africa (MEA) Arthropod-borne Viral Infections Testing Market
Request Purchase Now: https://www.futuremarketinsights.com/checkout/11572
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube